Abstract: EP1664
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Introduction: Alemtuzumab is a monoclonal antibody approved for the treatment of RRMS with clinical or radiological active disease. Alemtuzumab could be used as induction therapy or as second line treatment in the same way as in the clinical trials. But, it seems that the profile of patients treated with alemtuzumab in real world is quite different as in the clinical trials. The objective is to analyze the characteristics of patients who have started alemtuzumab in real life and the causes of switching.
Methods: Retrospective observational study including patients diagnosed with RRMS who received alemtuzumab in the last two years. Clinical examination and EDSS were performed before the treatment and every three months.
Results: We studied 20 RRMS patients of our MS center, 4of them were men. The average age was 43 years old (32-57), and the time from the first symptom of MS was 14 years. The average EDSS before treatment was 5.5 (2.5-7.0). All had previously been treated modifying treatment of the disease:25% with2treatments, 35% with 3 and 40% with4or more treatments.95% had previously received Natalizumab and in 40% it was the previously treatment to Alemtuzumab (In 35% was Fingolimod and in 20% Tecfidera). 84.2% of patients have switched due to an increase of clinical and radiological activity; 32% only due to clinical activity and 10.5% radiological activity. 35.7% had 2 relapses in the previous year, and 28.6%had more than3 relapses. 30% presented > 5 new hyperintense lesions in T2 and 50% had 2or more contrast-detecting lesions.
Conclusions: The profile of MS patient starting Alemtuzumab in our center is very different from the clinical trials. In real life they are very active patients with a longer disease duration, higher EDSS and treated with two or more therapies before alemtuzumab. It was not used as induction therapy.
Disclosure:
Elena Miñano-Guillamón: nothing to disclose.
Elena Guerra-Schulz: nothing to disclose
Inés González-Suarez Nothing to disclose
Marta Ortiz-Pica: Nothing to disclose
Ainhoa Arenaza-Peña: Nothing to disclose.
Celia Oreja-Guevara has received honoraria for speaking and/or consultancy from Biogen, Genzyme, Bayer, Merck, Roche, Teva and Novartis
Abstract: EP1664
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Introduction: Alemtuzumab is a monoclonal antibody approved for the treatment of RRMS with clinical or radiological active disease. Alemtuzumab could be used as induction therapy or as second line treatment in the same way as in the clinical trials. But, it seems that the profile of patients treated with alemtuzumab in real world is quite different as in the clinical trials. The objective is to analyze the characteristics of patients who have started alemtuzumab in real life and the causes of switching.
Methods: Retrospective observational study including patients diagnosed with RRMS who received alemtuzumab in the last two years. Clinical examination and EDSS were performed before the treatment and every three months.
Results: We studied 20 RRMS patients of our MS center, 4of them were men. The average age was 43 years old (32-57), and the time from the first symptom of MS was 14 years. The average EDSS before treatment was 5.5 (2.5-7.0). All had previously been treated modifying treatment of the disease:25% with2treatments, 35% with 3 and 40% with4or more treatments.95% had previously received Natalizumab and in 40% it was the previously treatment to Alemtuzumab (In 35% was Fingolimod and in 20% Tecfidera). 84.2% of patients have switched due to an increase of clinical and radiological activity; 32% only due to clinical activity and 10.5% radiological activity. 35.7% had 2 relapses in the previous year, and 28.6%had more than3 relapses. 30% presented > 5 new hyperintense lesions in T2 and 50% had 2or more contrast-detecting lesions.
Conclusions: The profile of MS patient starting Alemtuzumab in our center is very different from the clinical trials. In real life they are very active patients with a longer disease duration, higher EDSS and treated with two or more therapies before alemtuzumab. It was not used as induction therapy.
Disclosure:
Elena Miñano-Guillamón: nothing to disclose.
Elena Guerra-Schulz: nothing to disclose
Inés González-Suarez Nothing to disclose
Marta Ortiz-Pica: Nothing to disclose
Ainhoa Arenaza-Peña: Nothing to disclose.
Celia Oreja-Guevara has received honoraria for speaking and/or consultancy from Biogen, Genzyme, Bayer, Merck, Roche, Teva and Novartis